Back

Strategies for screening and identifying which patients to protect with the WCD.

18 March 2019 (13:05 - 13:20)
Organised by:
Congress Presentation Part of: Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death Prevention EHRA Premium Access EHRA 2019

About the speaker

Photo
Professor Joachim Ehrlich

St. Josefs- Hospital Wiesbaden, Wiesbaden (Germany)

4 More presentations in this session

Presentation thumbnail
Introduction - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.
Doctor G. Botto (Garbagnate Milanese, IT)
Slides Video
Presentation thumbnail
Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?
Doctor S. Reif (Munich, DE)
Slides Video
Presentation thumbnail
The impact of the WCD for patients who choose to wear it.
Professor D. Scherr (Graz, AT)
Slides Video
Presentation thumbnail
Panel discussion and summary - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.
Doctor O. Piot (Saint-Denis, FR)
Slides Video

Access the full session

Session thumbnail
Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death

The Event

Event poster

EHRA 2019

18 March 2019 13:05 CET
You may be interested in
thumbnail
Congress Session
Ventricular storm (2)
thumbnail
Webinar
The role of cardiac magnetic resonance for patients with ventricular arrhythmias and the prevention of sudden cardiac death in light of the 2022 ESC Guidelines
thumbnail
Congress Session
Hot topics in the management of ventricular tachycardia and sudden cardiac death

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources